According to Jin10, Novo Nordisk (NVO.N) said it filed a motion for a preliminary injunction in the U.S. District Court in New Jersey, seeking an immediate halt to Eli Lilly's (LLY.N) misleading GLP-1 advertising campaign while its lawsuit continues.
Aviso legal: Incluye opiniones de terceros. No es asesoramiento. Binance Ai puede utilizarse sin garantía.Consultar Términos y condiciones.
